Flamingo Therapeutics
Andrew Denker is currently serving as the Chief Medical Officer at Flamingo Therapeutics. Prior to this role, Andrew held positions as Vice President Early Development at ElevateBio, Vice President and Global Project Team Lead as well as Executive Director Global Medical Sciences at Alexion Pharmaceuticals, Inc. Andrew's extensive experience also includes roles at Merck, where Andrew served as Executive Director in Oncology Clinical Development and Senior Director in Clinical Development. Andrew Denker holds an MD and PhD in Biochemistry and Molecular Biology from Jefferson Health, and an AB in Molecular Biology from Princeton University.
This person is not in any teams
This person is not in any offices
Flamingo Therapeutics
Flamingo is pioneering RNA-targeted therapies for oncology with state-of-the art chemistries and a clinical-stage pipeline targeting undruggable transcription factors and splice variants. Flamingo Therapeutics has a Phase II trial (PEMDA-HN) evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC). Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Andera Partners, Bpifrance Large Venture, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, funds managed by Tekla Capital Management LLC and VIB.